PTO/SB/08A (08-00) proved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE persons are required to respond to a collection of information unless it contains a valid OMB control number Under the Paperwork

Substitute for Form 1449/A/PTO

Sheet

RADEMARY INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

of

Cor	nplete if Known
Application Number	09/929,819
Filing Date	July 31, 2001
First Named Inventor	R. Martin Emanuele
Group Art Unit	
Examiner Name	
Attorney Docket Number	19720-0626 42896-262529

				U.S. PATENT DOCUMENT		Pages Columbs, Lines Wilere
Examiner Loitials	Cite No.'	U.S. Patent D	ocument Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Relevant Passages or Relevant
72	1	Re 29,909		Kurtz	02-13-1979	TECH CENTER 1600/2900
11	2	2,674,619		Lundsted	10-15-1953	
1'-	3	2,854,378		Buckwalter	09-30-1958	
1	4	2,979,528		Lundsted	04-11-1961	
	5	3,022,335		Lundsted	02-20-1962	CODY
	6	3,036,118		Jackson, et al.	05-22-1962	COPY OF PAPERS
	7	3,089,818		Stone	05-14-1963	WALLY FILED
	8	3,140,232		Noseworthy	07-07-1964	
 	9	3,228,834		Gans, et al.	01-11-1966	
	10	3,450,502		Hymes	05-04-1971	
	11	3,577,522		Hymes	05-04-1971	
	12	3,590,125		Hymes	06-29-1971	
1	13	3,641,240		Hymes, et al.	02-08-1972	
	14	3,740,421		Schmolka	06-19-1973	
	15	3,867,521		Miskel, et al.	02-18-1975	
	16	3,956,259		Garcia, et al.	05-11-1976	
	17	4,073,886		Kehm	02-14-1978	
	18	4,100,271		Krezanoski	07-11-1978	
	19	4,323,560		Baschang, et al.	04-06-1982	
	20	4,395,393		Schmolka	07-26-1983	
 	21	4,407,790		Oakes, et al.	10-04-1983	
1	22	4,409,209		Baschang, et al.	10-11-1983	

			FOR	EIGN PATENT DOCUME	NTS		
Examiner Initials	Cite No.'	Foreign Patent Docu	ument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7*
RS	23	FR 2 081 436		R.P. Cherer Corporation	01-14-1971		
	24	DE 27 08 152		Flow Pharmaceuticals, Inc.	09-08-1977		\sqcup
	25	EP 0 000 704		Bayer AG	02-21-1979		
	26	EP 0 003 999		Hoechst Aktiengesellschaft	09-19-1979		\sqcup
	27	EP 0 011 237		Bayer AG			1
	28	EP 0 049 422		Miles Laboratories, Inc.	09-23-1981		$\perp \perp$
	29	EP 0 103 290		Intermedicat GMBH	09-10-1983		
	30	EP 0 121 752		Behringwerke AG	10-17-1984		
	31	PCT/US86/0174	17	Hunter et al.	08-25-1986		
	32	EP 0451880		Emory University	10-16-1991		\perp
	33	WO 91/19794		Novonordisk AS	12-26-1991		$oxed{oxed}$
52	34	WO 92/16484		CytRx Corporation	10-01-1992		

Examiner Signature Date Considered 1(3/03

'Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08A (08-00) proved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction 2003 1395, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

Sheet 2

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary of 7

Complete if Known					
Application Number	09/929,819				
Filing Date	July 31, 2001				
First Named Inventor	R. Martin Emanuele				
Group Art Unit					
Examiner Name					
Attorney Docket Number	19720-0626-(42896-262529)				

				U.S. PATENT DOCUMENT	rs	TOLIVED
Examiner Initials	Cite No.'	U.S. Patent I	Occument Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages Columns, Lines Where Relevant Pasages of Relevant Figures Appear
T/Z	35	4,410,660		Straus	10-18-1983 TE	CH CENTER 1800/2900
1	36	4,423,038		Baschang, et al.	12-27-1983	SII OLIVIEN 1000/2800
	37	4,489,158		Straus	12-18-1984	
	38	4,575,484		Straus	03-11-1986	PY OF PAPERS
	39	4,606,918		Allison, et al.	08-19-1986 QF	IGINALLY FILED
	40	4,609,546		Hiratani	09-02-1986	
	41	4,772,466		Allison, et al.	09-20-1988	
	42	4,801,452		Hunter, et al.	01-31-1989	
	43	4,837,014		Hunter, et al.	06-06-1989	
	44	4,869,900		Pozzi, et al.	09-26-1989	
	45	4,873,083		Hunter, et al.	10-10-1989	
	46	4,879,109		Hunter	11-07-1989	
	47	4,897,263		Hunter	01-30-1990	
	48	4,937,070		Hunter	06-26-1990	
	49	4,997,644		Hunter	03-05-1991	
	50	5,017,370		Hunter, et al.	05-21-1991	
	51	5,028,599		Hunter	07-02-1991	
	52	5,030,448		Hunter	07-09-1991	
1.	53	5,032,394		Hunter	07-16-1991	
	54	5,037,644		Shaked, et al.	08-06-1991	
	55	5,039,520		Hunter	08-13-1991	
28	56	5,041,288		Hunter	08-20-1991	

	T	Foreign Patent Document			EIGN PATENT DOCUME	Date of Publication of	Pages, Columns, Lines, Where	T
Examiner Initials	Cite No.'	Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Relevant Passages or Relevant Figures Appear	1
PS	57	W	O 93/08845		Massachusetts Institute of Technology	05-13-1993		
								+
		<u> </u>	<u> </u>					+
								-
								t
	1							
Examiner Signature		1/	(1) (Date Considered	1/3/05	

'Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08A (08-00) 2007 proved for use through 10/31/2002 OMB 0651-0031

MAR 0 5 2002 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Pape work Reduction Act of 1895, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Complete if Known					
Application Number	09/929,819				
Filing Date	July 31, 2001				
First Named Inventor	R. Martin Emanuele				
Group Art Unit					
Examiner Name					
Attorney Docket Number	19720-0626 (42896-262529)				

				U.S. PATENT DOCUMENT	rs	CEIVE
Examiner Anitials	Cite No.'	U.S. Patent Number		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant PASAGES or Relevant Figures Appear 2002
V	58	5,047,236		Hunter, et al.	09-10-1991	TECHON
7/	59	5,064,643		Hunter, et al.	11-12-1991	TECH CENTER 1600/2
	60	5,071,649		Hunter	12-10-1991	
	61	5,078,995		Hunter, et al.	01-07-1992	
	62	5,080,894		Hunter, et al.	01-14-1992	
	63	5,089,260		Hunter, et al.	02-18-1992	
	64	5,221,495		Cao	06-22-1993	
125	65	5,262,170		Anderson, et al.	11-16-1993	
			c	DOVOG		
			0	OPY OF PAPERS RIGINALLY FILED		
]		•			
			·			
	<u> </u>					
. •						

				FORE	IGN PATENT DOCUME	NTS	D. Out was Lines Miners	
		Fo	reign Patent Do	cument		Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or	۱_
Examiner Initials	Cite No.'	Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	MM-DD-YYYY	Relevant Figures Appear	7*
								┞-
								ļ
								┡
								├
								-
								╁
								╁-
								
								₩
								<u>i_</u>
			160					
Examiner Signature			Date Considered	1/3/03				

'Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language translation is attached.

COPY OF PAPERS ORIGINALLY FILED

PTO/SB/08B (08-00) Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no. prection of information unless it contains a valid OMB control number sons are require

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 4 of 7

nplete if Known
09/929,819
July 31, 2001 —
R. Martin Emanuele
Ξ , [
C & 7
19720-0626 (42896-262529)

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	<u>'ì</u>
	66	Atkinson, et al., "Ion Transport Mediated by Copolymers Composed of Polyoxyetherene	Ψ
2		and Polyoxypropylene," The American Physiological Society, 0363-6143/88, pp. C28-	
167		C26 (1988)	
/	67	Benner, et al., "Uber die Wirkung von Pluronic® F-68, einem Polyoxypropylen-	
		Polyoxyyyathylen-Kondensa auf die ADP-induzierte Thromobocytenaggregation in	- 1
		Vitro (The Effect of Pluronic® F-68, a Polyoxypropylene/Polyoxyethylene Condensate,	
		on ADP-Induced Platelet Aggregation in Vitro)", Pflugers Arch., Vol. 2, pp. 331-342	
		(1973)	
	68	Benner, et al., "Cold-Induced Platelet Aggregation in Vivo and Its Inhibition by a	
		Nonionic Surface Active Substance", Thrombosis Research, Vol. 2, pp. 331-342 (1973)	
	69	Block, et al., "Acutely Traumatized Canine Ureter Effects of Low Molecular Weight	İ
		Dextran and Surfactant Pluronic® F-68", Urology, Vol. 3, No. 2, pp. 190-194 (1974)	
	70	Block and Graft Copolymerization, Vol. 2, ed. By R. J. Ceresa, John Wiley & Sons	
		(1976)	
	71	D. J. A. I. G. Latin Course in Vassings to Eligit both Call Mediated and	
1 1	71	Byars, et al., Adjuvant formulation for us in Vaccines to Elicit both Cell-Mediated and	
,		Humoral Immunology", Vaccine, Vol. 5, pp. 223-228 (1987)	
	72	Confroth, et al., "Antituberculous Effect of Certain Surface-Active Ethylene Ethers in	
		Mice", Chemical Abstracts, Vol. 46, No. 2696 (1952)	
	73	Gaehtgens, et al., "Disaggregation of Human Red Blood Cells by Various Surface-	İ
		Active Agents as Related to Changes of Cell Shape and Hemolysis," Act. Heamat., Vol.	
		53, pp. 82-89 (1975)	
	74	Grover, et al., "A Non-Ionic Surfactant and Blood Viscosity", Arch. Surg., Vol. 106, pp.	
		307-310 (1973)	
	75	Grover, et al., "The Effect of Pluronic® F-68 on Circulatory Dynamics and Renal and	
		Carotid Artery Flow During Hemorrhagic Shock", Journal of Surgical Research, Vol.	
		17, pp. 30-35 (1974)	
	76	Hoie, et al., "Effects of Pluronic® F-68, Poloralkol, on Vascular Resistance in Vivo",	
		Journal of Surgical Research, Vol. 11, pp. 515-517 (1971)	
ļ	77	Hunter, et al., "Adjuvant Activity of Non-Ionic Block Copolymers.IV. Effect of	
DI		Molecular Weight and Formulation on Titre and Isotype of Antibody", Vaccine, Vol. 9,	
$ \langle \rangle \rangle$		pp. 250-256 (1991)	
L	1	T Pr. 200 200 (200)	

Date Examiner Considered Signature



PTO/SB/08B (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Across 29 to persons are required to respond to a collection of information unless it contains a valid OMB control number

MAR

To 1449/A/RTC

- - -

Substitute for Form 1449/A/PTO

INFORMATION DISCI STATEMENT BY APPLICANT

(use as many sheets as necessary

of 7 Sheet 5

nplete if Known	
09/929,819	
July 31, 2001	
R. Martin Emanuele 📿	
	₽
in in	. x
19720-0626 (42896-262529)	ئىز '
	09/929,819 July 31, 2001 日 R. Martin Emanuele 皇

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	~
Examiner Initials	Cite No.'	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	20,02
RS	Thromb. Haemost., Vol. 63, No. 1, pp. 6-12 (1990)		
	79	Hunter, et al., "Nonionic Block Copolymers Surfactants as Immunological Adjuvants: Mechanisms of Action and Novel Formulations", Immunological Adjuvants and Vaccines, pp. 133-144 (1989)	
	80	Hunter, et al., "The Adjuvant Activity of Nonionic Block Polymer Surfactants. I. The Role of Hydrophile-Lipophile Balance", J. Immun., Vol. 27, No. 3, pp. 1244-1250 (1981)	
Hunter, et al., "The Adjuvant Activity of Nonionic Block Polymer Surfactants. III. Characterization of Select Biologically Active Surfaces", Scand. J. Immunol., Vol. 23, pp. 287-300 (1986)		Characterization of Select Biologically Active Surfaces", Scand. J. Immunol., Vol. 23, pp. 287-300 (1986)	
	82	Hymes, et al., "The Influence of an Industrial Surfactant Pluronic® F-68, In the Treatment of Hemorrhagic Shock", Journal of Surgical Research, Vol. 11, pp. 191-197 (1971)	
	83	Ketchum, et al., "Experimental Use of Pluronic® F-68 in Microvascular Surgery", Plastic and Reconstructive Surgery, Vo 53, pp. 288-292 (1974)	
	84	Ketchum, L.D., "Pharmacological Alterations in the Clotting Mechanism: Use In Microvascular Surgery", <i>Journal of Hand Surgery</i> , Vol. 3, pp. 407-415 (1978)	
	85	Knize, et al., "Use of Antisludging Agents in Experimental Cold Injuries", Surgery, Gynecology & Obstetric, Vol. 129, pp. 1019 (1969)	
	86	Kondo, et al., "Prolonged Suspended Animation in Puppies", Cryobiology, Vol.11, No. 5, pp. 446-451 (1974)	
	87	Lane, et al., "Reduction in the Toxicity of a Component of an Artificial Blood Substitute by Supercritical Fluid Fractionation", Transfusion, Vol. 28, pp. 375-378 (1987)	
	88	Matsukara, et al., "Phosphorothioate Analogs of Oligodeoxynucleotides: Inhibitors of Replication and Cytopathic Effects of Human Immunodeficiency Virus", Proc. Natl. Acad. Sci. USA, Vol. 84, pp. 7706 (1987)	
725	89	Mezrow, et al., "Poloxamer 188 Improves Neurological Outcome after Hypothermic Circulatory Arrest," J. Thorac. Cardiovas. Surg., Vol. 103, No. 6, pp. 1143-1146 (1992)	

		4	 			
Examiner Signature	W	// ₋ V	Date Considered	1/	3/0	

PTO/SB/08B (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ons are required to respond to a collection of information unless it contains a valid OMB control number Under the Paperwork Reduction Rect of

Substitute for Form 1449/A/PTO

Sheet 6

INFORMATION DISCLO STATEMENT BY APPLICANT

(use as many sheets as necessary

of 7

Complete if Known			
Application Number	09/929,819 OF GALLEY		
Filing Date	July 31, 2001		
First Named Inventor	R. Martin Emanuel		
Group Art Unit			
Examiner Name			
Attornov Docket Number	10720_0626 (42896-262529)		

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS
Examiner Initials	Cite No.'	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
\mathcal{T} 90		Moore, et al., "Reduction of Splenic Vascular Resistance During Profusion by 1 2 2002
1		Pluronic®F-68", Journal Surgical Research, Vol. 8, pp. 563-566 (1968)
	91	Nagata, et al., "Clinical Evaluation on the Effect of Poloxamer 188 on the Heffel 15 1600/2900 During Cardiopulmonary Bypass", J. Aichi. Med. Univ. Assoc., Vol. 11, No. 1, pp. 48-54 (1983)
	92	Papadea, et al., "Effect of RheothRx TM Copolymer on Blood Viscosity Related to Fibrin (ogen) Concentration", Faseb J., Vol. 2, No. 4, pp.A384A, Abstract 512 (1988)
	93	Paton, et al., "The Use of a Nonionic Detergent Added to Organ Perfusates", Organ Perfusion and Preserv., pp. 105-120 (1968)
	94	Rodeheaver, G.T., "Pluronic® F-68: A Promising New Skin Wound Cleanser", Ann Emerg. Med., Vol. 9, No. 11, pp. 572-576 (1980)
	95	Rodeheaver, et al., "Mechanical Cleansing of Contaminated Wounds with a Surfactant", J. Biochem. Interactions, Vol. 83, pp. 153-1510s (1975)
	96	Sakauchi, "Prevention of Excess Hemolysis During Cardiopulmonary Bypass by the Use of Pluronic® F-68", Kitakanto Med. J., Vol. 23, No. 3, pp. 231-238 (1973)
	97	Schmolka, et al., "Artificial Skin I. Preparation and Properties of Pluronic® F-127 Gels for Treatment of Burns, "J. Biomed. Mater. Res., Vol. 6, pp. 571-582 (1972)
	98	Schmolka, "A Review of Block Polymer Surfactants", Journal of the American Oil Chemists Society, Vol. 54, No. 3, pp. 110-116 (1977)
	99	Snippe, et al., "Adjuvant Effect of Nonionic Block Polymer Surfactants in Humoral and Cellular Immuniology", Int. Archs. Allergy Appl. Immun., Vol. 65, pp. 390-398 (1981)
	100	Takayama, et al., "Adjuvant Activity of Non-Ionic Block Copolymers.V. Modulation of Antibody Isotype Lipopolysaccharides, Lipid A and Precursors," Vaccine, Vol. 9, pp. 257-265 (1991)
PS	101	Technical Bulletin entitled "Performance Chemicals"

	/ M		
Examiner Signature	Why al	Date Considered	1/3/03

PTO/SB/08B (08-00) proved for use through 10/31/2002 OMB 0651-0031

MAR 0 5 2002 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ns are required to respond to a collection of information unless it contains a valid OMB control number Under the Paperwork Reduction Act of 1995, no pe

Substitute for Form 1449/A/PTO

Sheet

Examiner

Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Cor	nplete if Known
Application Number	09/929,819
Filing Date	July 31, 2001
First Named Inventor	R. Martin Emanuele
Group Art Unit	
Examiner Name	DEOF
Attorney Docket Number	19720-0626 (42896-252529) V

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Examiner Initials publisher, city and/or country where published TECH CENTER 1600/2900 Technical Bulletin entitled "Pluronic®Block Copolymer Surfactants" 102 Vasko, et al., Poloxalkol® (Pluronic® F-68): A Priming Solution for Cardiopulmonary 103 Bypass", Trans. Am. Soc. Artif. Int. Organs, Vol. 18, pp. 526-531 (1972) William, et al., "Modulation of Rat Granulocyte Traffic by a Surface Active Agent in 104 Vitro and Bleomycin Injury", Proceedings of the Society for Experimental Biology and Medicine, Vol. 188, pp. 461-470 (1988)

Date

Considered